<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999241</url>
  </required_header>
  <id_info>
    <org_study_id>UC1.2</org_study_id>
    <nct_id>NCT04999241</nct_id>
  </id_info>
  <brief_title>Combined Application of EEN in the Induction of Remission in PUC</brief_title>
  <official_title>The Role of Combined Application of Exclusive Enteral Nutrition in the Induction of Remission for Children With Newly Diagnosed Moderate to Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of exclusive enteral nutrition (EEN) in the induction of remission in pediatric&#xD;
      patients with Crohn's disease had been well documented. But the role of EEN in children with&#xD;
      Ulcerative Colitis (UC) was not clear. In this study, EEN will be combined with&#xD;
      corticosteroids or infliximab in the induction of remission in pediatric UC patients with&#xD;
      moderate to severe disease activity. The mucosal healing rate at week12 will be compared&#xD;
      between the two groups (combine with EEN group VS non-combine group).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of exclusive enteral nutrition (EEN) in the induction of remission in pediatric&#xD;
      patients with Crohn's disease(CD) had been well documented. Several randomized controlled&#xD;
      trial studies found that the overall induction of remission was equipotent with EEN compared&#xD;
      to corticosteroids for pediatric CD. However, in promoting mucosal healing and improving the&#xD;
      nutritional status, EEN was much better than corticosteroids. But the role of EEN in children&#xD;
      with Ulcerative Colitis (UC) was not clear. In this study, EEN will be combined with&#xD;
      corticosteroids or infliximab in the induction of remission in pediatric UC patients with&#xD;
      moderate to severe disease activity. The mucosal healing rate at week 12 will be compared&#xD;
      between the two groups (combine with EEN group VS non-combine group).The sustained&#xD;
      corticosteroid-free clinical remission rate and treatment modification rate during the first&#xD;
      year will also be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mucosal healing rate</measure>
    <time_frame>12 week after intervention</time_frame>
    <description>The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) â‰¦1 points is defined as mucosal healing. This will be evaluated by inflammatory bowel disease endoscopist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sustained corticosteroid-free clinical remission rate</measure>
    <time_frame>1 year after intervention</time_frame>
    <description>Sustained pediatric Ulcerative Colitis activity index (PUCAI) score &lt;10 points during follow-up (week 14 to week 54 after intervention) without the treatment of corticosteroids . This will be evaluated by gastroenterologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment modification rate</measure>
    <time_frame>1 year after intervention</time_frame>
    <description>The rate of new treatment measures needed to be started due to worsening of symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Exclusive Enteral Nutrition</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>EEN combined therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in the induction of remission phase, EEN will be used combine with corticosteroids or infliximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non EEN combination group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in the induction of remission phase, corticosteroids or infliximab will be used without EEN</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>exclusive enteral nutrition</intervention_name>
    <description>Administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks, then patients can administration of regular food.</description>
    <arm_group_label>EEN combined therapy group</arm_group_label>
    <other_name>corticosteroids, infliximab, 5-ASA, AZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>regular food</intervention_name>
    <description>Administration of regular food in the induction phase and the later time.</description>
    <arm_group_label>Non EEN combination group</arm_group_label>
    <other_name>corticosteroids, infliximab, 5-ASA, AZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed UC&#xD;
&#xD;
          2. Years 6 to 18&#xD;
&#xD;
          3. Moderate to severe disease activity at diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With mild disease activity at diagnosis&#xD;
&#xD;
          2. Had been treated with corticosteroids or biologics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Huang</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cui fang Zheng</last_name>
    <phone>8615221881022</phone>
    <email>zhengcuifang2@126.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Ying HUANG</investigator_full_name>
    <investigator_title>Chief of Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

